加拿大 -
英文 -
Health Canada
sandoz fentanyl patch
sandoz canada incorporated - fentanyl - patch - 37mcg - fentanyl 37mcg - opiate agonists
加拿大 -
英文 -
Health Canada
sandoz fentanyl patch
sandoz canada incorporated - fentanyl - patch - 50mcg - fentanyl 50mcg - opiate agonists
加拿大 -
英文 -
Health Canada
sandoz fentanyl patch
sandoz canada incorporated - fentanyl - patch - 75mcg - fentanyl 75mcg - opiate agonists
加拿大 -
英文 -
Health Canada
sandoz fentanyl patch
sandoz canada incorporated - fentanyl - patch - 100mcg - fentanyl 100mcg - opiate agonists
加拿大 -
英文 -
Health Canada
mylan-fentanyl matrix patch
mylan pharmaceuticals ulc - fentanyl - patch - 12mcg - fentanyl 12mcg - opiate agonists
加拿大 -
英文 -
Health Canada
mylan-fentanyl matrix patch
mylan pharmaceuticals ulc - fentanyl - patch - 25mcg - fentanyl 25mcg - opiate agonists
加拿大 -
英文 -
Health Canada
mylan-fentanyl matrix patch
mylan pharmaceuticals ulc - fentanyl - patch - 50mcg - fentanyl 50mcg - opiate agonists
加拿大 -
英文 -
Health Canada
mylan-fentanyl matrix patch
mylan pharmaceuticals ulc - fentanyl - patch - 75mcg - fentanyl 75mcg - opiate agonists
加拿大 -
英文 -
Health Canada
mylan-fentanyl matrix patch
mylan pharmaceuticals ulc - fentanyl - patch - 100mcg - fentanyl 100mcg - opiate agonists
美国 -
英文 -
NLM (National Library of Medicine)
rivastigmine transdermal system patch, extended release
alvogen inc. - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine 4.6 mg - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer’s type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer’s disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-